EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The European Union’s Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks

Mondher Toumi iD, Imen Soussi, Bruno Falissard, Steven Simoens iD, Asma Jouini iD, Maarten Postma, Juergen Wasem iD, Oriol Solà-Morales iD, Laurent Boyer iD, Claude Dussart, Borislav Borissov iD, Renato Bernardini und 3 weitere

Journal of Market Access & Health Policy · 03.08.2026 · 14 (3) · 45

DOI: 10.3390/jmahp14030045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Market Access & Health Policy, online erschienen am 03.08.2026. Verfasst von Mondher Toumi und 14 weiteren Autor:innen. Beteiligte Einrichtung: CEReSS/UR3279-Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The EU Health Technology Assessment Regulation (EU-HTA R), effective January 2025, mandates Joint Clinical Assessments (JCAs) to harmonize HTA across Member States. However, its implementation raises fundamental questions about methodological coherence, institutional capacity, and epistemological alignment.

Objectives

This manuscript (1) systematically assesses whether the stated strategic and operational objectives of the EU-HTA R are achievable under current implementation conditions; (2) examines the implications for EU institutional legitimacy if these objectives are not met; and (3) proposes an epistemological framework as a prerequisite for developing a coherent joint HTA methodology.

Methods

We conducted a critical policy analysis of the EU-HTA R, its implementing guidance documents, and published templates, supplemented by a comparative review of Member State HTA methodologies and their underlying philosophical foundations.

Results

The analysis reveals that the EU-HTA R is unlikely to achieve its strategic goals under current conditions. Key findings include: guidance documents of substandard methodological quality; a restricted assessment scope that excludes scientific judgement and contextualization; insufficient resources and additional workload for national HTA bodies without reducing existing obligations; unresolved epistemological divergences among Member States spanning Bayesian vs. frequentist approaches, Fisher vs. Neyman–Pearson frameworks, and utilitarian vs. deontological ethical foundations; and procedural shortcomings in stakeholder consultation and expert involvement. These shortcomings risk undermining the epistemic authority and legitimacy of EU institutions.

Conclusions

Prior epistemological and normative alignment across Member States is a prerequisite for any robust shared HTA methodology. Revisions to the EU-HTA R and comprehensive updates of guidance documents are necessary, with concrete safeguards—including independent peer review, identified authorship, and adequate resourcing—to ensure substantive rather than merely nominal implementation. A phased roadmap is proposed: establishing clear objectives, aligning epistemological foundations, developing institutional structures, and creating operationally consistent guidance.

Schlagwörter

Stichwörter der Autor:innen

EU-HTAdisguisedsemantic HTA EU-HTA regulationwords signification

Autor:innen und Institutionen

  • CEReSS/UR3279-Health Services Research and Quality of Life Center, Aix-Marseille University, 13385 Marseille, France.
  • Clever Access, Tunis 1058, Tunisia.
  • CESP, INSERM U1018, Université Paris-Saclay, 94800 Villejuif, France.
  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
  • Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 AB Groningen, The Netherlands.
  • Faculty for Economics and Business Administration, Institute for Health Care Management and Research, University Duisburg-Essen, 45127 Essen, Germany.

ORCID-Profile: Mondher Toumi, Steven Simoens, Asma Jouini, Juergen Wasem, Oriol Solà-Morales, Laurent Boyer, Borislav Borissov, Stefano Capri, Jaime Espin, Pascal Auquier

Zitieren

APA

Toumi, M., Soussi, I., Falissard, B., Simoens, S., Jouini, A., Postma, M., Wasem, J., Solà-Morales, O., Boyer, L., Dussart, C., Borissov, B., Bernardini, R., Capri, S., Espin, J., & Auquier, P. (2026). The European Union’s Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks. Journal of Market Access & Health Policy, 14(3), 45. https://doi.org/10.3390/jmahp14030045

Vancouver

Toumi M, Soussi I, Falissard B, Simoens S, Jouini A, Postma M, et al. The European Union’s Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks. Journal of Market Access & Health Policy. 2026;14(3):45. doi:10.3390/jmahp14030045

BibTeX
@article{Toumi2026,
  author = {Toumi, Mondher and Soussi, Imen and Falissard, Bruno and Simoens, Steven and Jouini, Asma and Postma, Maarten and Wasem, Juergen and Solà-Morales, Oriol and Boyer, Laurent and Dussart, Claude and Borissov, Borislav and Bernardini, Renato and Capri, Stefano and Espin, Jaime and Auquier, Pascal},
  title = {The European Union’s Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks},
  journal = {Journal of Market Access & Health Policy},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {45},
  doi = {10.3390/jmahp14030045}
}
Kostenlos starten →